GAD and IA-2 autoantibody detection in type 1 diabetic patient saliva

Claudio Tiberti, Blegina Shashaj, Antonella Verrienti, Elio Giancarlo Vecci, Federica Lucantoni, Donata Masotti, Susanna Morano, Nicoletta Sulli, Francesco Dotta

Research output: Contribution to journalArticlepeer-review


Some attempts have been made in assaying glutamic-acid decarboxylase autoantibodies (GADA) in type 1 diabetic patient (T1DM) saliva. However, these salivary assays did not show sufficient sensitivity and specificity in comparison to serum assays. In this study we evaluated the ability of a fluid-phase 35S-radioimmunoassay to detect GADA and tyrosine phosphatase 2 autoantibodies (IA-2A) in 70 T1DM, 24 T1DM first degree relatives (FDR) and 76 healthy subject saliva. Paired saliva and serum samples were collected from each subject and analyzed. GADA were detected in 45/70 (64.3%) sera and 43/70 (61.4%) T1DM saliva, respectively. IA-2A were detected in 33/70 (47.1%) sera and 30/70 (42.9%) T1DM saliva, respectively. All FDR serum/saliva samples were autoantibody negative. In conclusion, we here report that GADA and IA-2A are detectable with high sensitivity and specificity in human saliva, a specimen which can be easily collected by non-invasive procedures and may represent a reliable tool for the study of T1DM autoimmunity.

Original languageEnglish
Pages (from-to)271-276
Number of pages6
JournalClinical Immunology
Issue number2
Publication statusPublished - May 2009


  • GAD autoantibodies
  • Human saliva
  • IA-2 autoantibodies
  • Type 1 diabetes

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy


Dive into the research topics of 'GAD and IA-2 autoantibody detection in type 1 diabetic patient saliva'. Together they form a unique fingerprint.

Cite this